ORBi: Detailled Reference

Article (Scientific journals)

Des statines pour le cerveau?

Sadzot, Bernard; HANS, Grégory; Bottin, P. et al.

2003 • In Revue Médicale de Liège, 58 (10), p. 621-7

Peer reviewed

Permalink
https://hdl.handle.net/2268/181736

PubMed
14677521

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

200310_07.pdf

Publisher postprint (466.47 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Brain/physiology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology; Hypercholesterolemia/complications/prevention & control; Incidence; Stroke/physiopathology/prevention & control

Abstract :

[en] Whether cholesterol lowering decreases risk of stroke has long remained unclear. Large epidemiological studies have found only weak links between cholesterol levels and stroke. Recent studies with statins, more potent cholesterol lowering agents, have now demonstrated significant reductions of stroke incidence and total mortality when administered for secondary prevention in patients with wide ranges of cholesterol values. It remains unknown if a statin is superior to others for the secondary prevention of stroke.

Disciplines :

Neurology

Author, co-author :

Sadzot, Bernard ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

HANS, Grégory ; Centre Hospitalier Universitaire de Liège - CHU > Anesthésie et réanimation

Bottin, P.

Moonen, Gustave ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Des statines pour le cerveau?

Alternative titles :

[en] Statins for the brain?

Publication date :

2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

58

Issue :

10

Pages :

621-7

Peer reviewed :

Peer reviewed

Available on ORBi :

since 21 May 2015

Statistics

Number of views

60 (7 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

4

Scopus citations^®
without self-citations

2

Bibliography

Eastern Stroke and Coronary Heart Disease Collaborative Research Group.- Blood pressure, cholesterol, and stroke in eastern Asia. Lancet, 1998, 352, 1801-1807.
Murray CJ, Lopez AD.- Links Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 1997, 349, 1269-1276.
Wolf PA, Kannel WB, Verter J.- Current status of risk factors for stroke. Neurol Clin, 1983, 1, 317-343.
Khaw KT.- Epidemiology of stroke. J Neurol Neurosurg Psychiatry, 1996, 61, 333-338.
LaRosa JC, Hunninghake D, Bush D, et al.- The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation, 1990, 81, 1721-1733.
Law MR, Wald NJ, Wu T, et al.- Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ, 1994, 308, 363-366.
Pekkanen J, Linn S, Heiss G, et al.- Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med, 1990, 322, 1700-1707.
Stamler J, Wentworth D, Neaton JD.- Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 1986, 256, 2823-2828.
Wong ND, Wilson PW, Kannel WB.- Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med, 1991, 115, 687-693.
Grundy SM.- Statin trials and goals of cholesterol-lowering therapy. Circulation, 1998, 97, 1436-1439.
Holme I.- An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation, 1990, 82, 1916-1924.
Rossouw JE, Lewis B, Rifkind BM.- The value of lowering cholesterol after myocardial infarction. N Engl J Med, 1990, 323, 1112-1119.
Heart Protection Study Collaborative Group.- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.
Kannel WB, Dawber TR, Cohen ME, McNamara PM. - Vascular disease of the brain - epidemiological aspects: the Framingham Study. Am J Public Health, 1965, 55, 1355-1366.
Prospective studies collaboration.- Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet, 1995, 346, 1647-1653.
Lindenstrom E, Boysen G, Nyboe J.- Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ, 1994, 309, 11-15.
Kagan A, Popper JS, Rhoads GG.- Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study. Stroke, 1980, 11, 14-21.
Benfante R, Yano K, Hwang LJ, et al.- Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke, 1994, 25, 814-820.
Iso H, Jacobs DR Jr, Wentworth D, et al.- Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med, 1989, 320, 904-910.
Yano K, Reed DM, MacLean CJ.- Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke, 1989, 20, 1460-1465.
Byington RP, Davis BR, Plehn JF, et al.- Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation, 2001, 103, 387-392.
Sacks FM, Tonkin AM, Shepherd J, et al.- Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation, 2000, 102, 1893-1900.
Scandinavian Simvastatin Survival Study (4S).- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet, 1994, 344, 1383-1389.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998, 339, 1349-1357.
Atkins D, Psaty BM, Koepsell TD, et al.- Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med, 1993, 119, 136-145.
Hebert PR, Gaziano JM, Hennekens CH.- Links An overview of trials of cholesterol lowering and risk of stroke. Intern Med, 1995, 155, 50-55.
Hebert PR, Gaziano JM, Chan KS, Hennekens CH.- Links Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA, 1997, 278, 313-321.
American Heart Association.- 1992 Heart and Stroke Facts. Dallas, Texas: American Heart Association National Center; 1992.
Knopp RH.- Drug treatment of lipid disorders. N Engl J Med, 1999, 341, 498-511.
Martin R, Bogousslavsky J.- Mechanism of late stroke after myocardial infarct: the Lausanne Stroke Registry. J Neurol Neurosurg Psychiatry, 1993, 56, 760-764.
Plehn JF, Davis BR, Sacks FM, et al.- Reduction of stroke Incidence After Myocardial Infarction With Pravastatin: The Cholesterol and Recurrent Events (CARE) Study. Circulation, 1999, 99, 216-223.
Sacks FM, Pfeffer MA, Moye LA, et al.- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996, 335, 1001-1009.
White HD, Simes RJ, Anderson NE, et al.- Pravastatin therapy and the risk of stroke. N Engl J Med, 2000, 343, 317-326.
Waters DD, Schwartz GG, Olsson AG, et al.- Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy. Circulation, 2002, 106, 1690-1695.
Kulbertus H, Scheen AJ.- L'étude clinique du mois. La MRC/BHF Heart Protection Study. Rev Med Liege, 2002, 57, 613-616.
Shepherd J, Blauw GJ, Murphy MB, et al.- Pravastatin in elderly individuals at risk of vascular disease (PROS-PER): a randomised controlled trial. Lancet, 2002, 360, 1623-1630.
Shepherd J, Cobbe SM, Ford I, et al.- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333, 1301-1307.
Crouse JR 3rd, Byington RP, Hoen HM, Furberg CD.- Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med, 1997, 157, 1305-1310.
Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG.- Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke, 1997, 28, 946-950.
Bucher HC, Griffith LE, Guyatt GH.- Effect of HMG-coA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med, 1998, 128, 89-95.
Lau WC, Waskell LA, Watkins PB, et al.- Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation, 2003, 107, 32-37.
Chambers BR, Norris JW.- Outcome in patients with asymptomatic neck bruits. N Engl J Med, 1986, 315, 860-865.
Grotta JC, Yatsu FM, Pettigrew LC, et al.- Prediction of carotid stenosis progression by lipid and hematologic measurements. Neurology, 1989, 39, 1325-1331.
MAAS Investigators.- Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet, 1994, 344, 633-638.
Crouse JR 3rd, Byington RP, Bond MG, et al.- Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol, 1995, 75, 455-459.
Hodis HN, Mack WJ, LaBree L, et al.- Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med, 1996, 124, 548-556.
MacMahon S, Sharpe N, Gamble G, et al.- Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation, 1998, 97, 1784-1790.
Mercuri M, Bond MG, Sirtori CR, et al.- Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med, 1996, 101, 627-634.
Salonen R, Nyyssonen K, Porkkala E, et al.- Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation, 1995, 92, 1758-1764.
Fassbender K, Stroick M, Bertsch T, et al.- Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology, 2002, 59, 1257-1258.
Wolozin B, Kellman W, Ruosseau P, et al.- Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol, 2000, 57, 1439-1443.
Jick H, Zornberg GL, Jick SS, et al.- Statins and the risk of dementia. Lancet, 2000, 356, 1627-1631.
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults.- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
Wood D, De Backer G, Faergeman O, et al.- Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Blood Press, 1998, 7, 262-269.
Loh E, Sutton MS, Wun CC, et al.- Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med, 1997, 336, 251-257.
Gorelick PB.- Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke, 2002, 33, 862-875.
Rosenson RS, Tangney CC.- Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA, 1998, 279, 1643-1650.
Delanty N, Vaughan CJ.- Vascular effects of statins in stroke. Stroke, 1997, 28, 2315-2320.
Vaughan CJ, Murphy MB, Buckley BM.- Statins do more than just lower cholesterol. Lancet, 1996, 348, 1079-1082.
Undas A, Brummel KE, Musial J, et al.- Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation, 2001, 103, 2248-2253.
Lacoste L, Lam JY, Hung J, et al.- Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation, 1995, 92, 3172-3177.
Amin-Hanjani S, Stagliano NE, Yamada M, et al.- Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke, 2001, 32, 980-986.
Endres M, Laufs U, Huang Z, et al.- Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA, 1998, 95, 8880-8885.
Laufs U, Liao JK.- Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med, 2000, 10, 143-148.
Callahan A.- Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol, 2001, 88(7B), 33J-37J.
Major ongoing stroke trials: stroke prevention by aggressive reduction in cholesterol levels (SPARCL). Stroke, 2001, 32, 589.
Antiplatelet Trialists' Collaboration.- Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 1994, 308, 81-106.

Similar publications